T6272

Fosbretabulin Disodium (CA 4P), a water-soluble prodrug of Combretastatin A4 (CA4), is a microtubule-targeting agent that binds β-tubulin (Kd: 0.4 μM). Fosbretabulin Disodium(Combretastatin A4 disodium phosphate) inhibits the polymerization of tubulin (IC50: 2.4 μM), and also disrupts tumor vasculature.

CBP/p300-IN-18 (compound 8) is a potent inhibitor of EP300/CBP HAT, with an IC50 of 0.056 μM for HAT EP300 and 0.46 μM for LK2 H3K27.

CPI-1612 is a potent, orally active EP300/CBP histone acetyltransferase (HAT) inhibitor that acts on EP300 HAT (IC50: 8.1 nM). CPI-1612 exhibits anticancer effects.

RIPK1-IN-12 is a potent inhibitor of RIPK1, exhibiting an inhibitory effect on necroptosis in human and mouse cells with EC50 values of 1.6 and 2.9 nM, respectively.

AQX-435 is a potent activator of SHIP1 (SH2 domain-containing inositol-5′-phosphatase 1). AQX-435 decreases B-cell receptor (BCR) downstream PI3K activity, induces apoptosis in malignant B cells, and exhibits inhibitory effects on lymphoma growth.

IDH1 Inhibitor 5 (compound 2) is an IDH1 (isocitrate dehydrogenase 1) inhibitor with an IC50 of 64.4 nM for MOG cells and an IC50 of 34.9 nM for wild-type IDH1 glioma cells expressing exogenous mutant IDH1 R132H protein.

Phenylpyropene C (S14-95) is a JAK/STAT pathway inhibitor that exhibits inhibition of IFN-γ-mediated reporter gene expression (IC50: 5.4-10.8 μM) and is also an inhibitor of acyl coenzyme A (IC50: 16.0 μM).

NRP1 antagonist 1 is a potent and non-peptide NRP1 antagonist with IC50=19.1 μM that has anti-tumor potential by blocking VEGF-NRP interactions.

AChE-IN-24 is a potent inhibitor of AChE that crosses the blood-brain barrier, strongly inhibiting hAChE (IC50: 0.053 μM). AChE-IN-24 can be used to study Alzheimer's disease (AD).